Top

Published in:

01-07-2013 | Original Article

A novel recombinant protein of IP10-EGFRvIIIscFv and CD8⁺ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice

Authors: Xuan Wang, Xiao-Ling Lu, Hong-Yang Zhao, Fang-Cheng Zhang, Xiao-Bing Jiang

Published in: Cancer Immunology, Immunotherapy | Issue 7/2013

Abstract

The epidermal growth factor receptor (EGFR) mutant of EGFRvIII is highly expressed on glioma cells and has been thought to be an excellent target molecule for immunotherapy. IP-10 is a potent chemokine and can recruit CXCR3⁺ T cells, including CD8⁺ T cells that are important for the control of tumor growth. This study is aimed at investigating the therapeutic efficacy of a novel fusion protein of IP10-EGFRvIIIscFv (IP10-scFv) in combination with glioma lysate-pulsed DCs-activated CD8⁺ cytotoxic T lymphocytes (CTLs) in a mouse model of glioma. A plasmid of pET-IP10-scFv was generated by linking mouse IP-10 gene with the DNA fragment for anti-EGFRvIIIscFv, a (Gly₄Ser)₃ flexible linker and a His-tag. The recombinant IP10-scFv in E. coli was purified by affinity chromatography and characterized for its anti-EGFRvIII immunoreactivity and chemotactic activity. C57BL/6 mice were inoculated with mouse glioma GL261 cells in the brain and treated intracranially with IP10-scFv and/or intravenously with CTL for evaluating the therapeutic effect. The glioma-specific immune responses were examined. The IP10-scFv retained anti-EGFRvIII immunoreactivity and IP-10-like chemotactic activity. Treatment with both IP10-scFv and CTL synergistically inhibited the growth of glioma and prolonged the survival of tumor-bearing mice, accompanied by increasing the numbers of brain-infiltrating lymphocytes (BILs) and the frequency of CXCR3⁺CD8⁺ T cells, enhancing glioma-specific IFN-γ responses and cytotoxicity, and promoting glioma cell apoptosis in mice. Our novel data indicate that IP10-scFv and CTL have synergistic therapeutic effects on inhibiting the growth of mouse glioma in vivo.

Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19(4):713–723PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

Lu XL, Jiang XB, Liu RE, Zhang SM (2008) The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 26(42):5352–5357PubMedCrossRef

Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+T lymphocytes but not inhibition of angiogenesis. J Immunother 28(4):343–351PubMedCrossRef

Wang P, Yang X, Xu W, Li K, Chu Y, Xiong S (2010) Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 59(11):1715–1726PubMedCrossRef

Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, Nierkens S, Adema GJ (2008) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122(8):1794–1802PubMedCrossRef

Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16(6):748–754PubMedCrossRef

Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Criniere E, Carvalho Silva R, Laigle-Donadey F, Rousseau A, Mokhtari K, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY (2009) Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol 35(2):208–213PubMedCrossRef

Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K (2007) Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25(16):2288–2294PubMedCrossRef

10.

Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27(4):502–520PubMedCrossRef

11.

Kortt AA, Dolezal O, Power BE, Hudson PJ (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18(3):95–108PubMedCrossRef

12.

Penichet ML, Morrison SL (2001) Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248(1–2):91–101PubMedCrossRef

13.

Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW (2000) Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 27(4):339–346PubMedCrossRef

14.

Jiang XB, Lu XL, Hu P, Liu RE (2009) Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 27(44):6210–6216PubMedCrossRef

15.

Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25):14815–14820PubMedCrossRef

16.

Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247–4254PubMed

17.

Guo JQ, Li QM, Zhou JY, Zhang GP, Yang YY, Xing GX, Zhao D, You SY, Zhang CY (2006) Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system. Protein Expr Purif 45(1):168–174PubMedCrossRef

18.

Bu N, Wu H, Sun B, Zhang G, Zhan S, Zhang R, Zhou L (2011) Exosome-loaded dendritic cells elicit tumor-specific CD8⁺ cytotoxic T cells in patients with glioma. J Neurooncol 104(3):659–667PubMedCrossRef

19.

Brasel K, De Smedt T, Smith JL, Maliszewski CR (2000) Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96(9):3029–3039PubMed

20.

Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Ruegg C, Dietrich PY, Walker PR (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22(2):175–184PubMedCrossRef

21.

Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 8:21PubMedCrossRef

22.

Schaer DA, Li Y, Merghoub T, Rizzuto GA, Shemesh A, Cohen AD, Avogadri F, Toledo-Crow R, Houghton AN, Wolchok JD (2011) Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PLoS ONE 6(6):e21214PubMedCrossRef

23.

Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57(18):4130–4140PubMed

24.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–854PubMedCrossRef

25.

Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6(5):383–393PubMedCrossRef

26.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129PubMedCrossRef

27.

Ogasawara K, Hida S, Weng Y, Saiura A, Sato K, Takayanagi H, Sakaguchi S, Yokochi T, Kodama T, Naitoh M, De Martino JA, Taniguchi T (2002) Requirement of the IFN-alpha/beta-induced CXCR3 chemokine signalling for CD8+T cell activation. Genes Cells 7(3):309–320PubMedCrossRef

28.

Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, Kiessling F, Paschek S, Sozzani S, Rommelaere J, Cornelis JJ, Van Damme J, Dinsart C (2009) TNF-alpha and the IFN-gamma-inducible protein 10(IP-10/CXCL10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16(2):149–160PubMedCrossRef

29.

Liu M, Guo S, Stiles JK (2011) The emerging role of CXCL10 in cancer. Oncol Lett 2(4):583–589PubMed

30.

Berk E, Muthuswamy R, Kalinski P (2012) Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine 30(43):6216–62224PubMedCrossRef

31.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360PubMedCrossRef

32.

Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294–298PubMedCrossRef

33.

Blohm U, Potthoff D, van der Kogel AJ, Pircher H (2006) Solid tumors “melt” from the inside after successful CD8 T cell attack. Eur J Immunol 36(2):468–477PubMedCrossRef

34.

Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201(2):249–257PubMedCrossRef

35.

Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C (2005) T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 11(11):1222–1229PubMedCrossRef

36.

Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H (2009) Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 69(4):1587–1595PubMedCrossRef

Title: A novel recombinant protein of IP10-EGFRvIIIscFv and CD8+ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice
Authors: Xuan Wang
Xiao-Ling Lu
Hong-Yang Zhao
Fang-Cheng Zhang
Xiao-Bing Jiang
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1426-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors

Immune-suppressive properties of the tumor microenvironment

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

Keynote webinar | Spotlight on antibody–drug conjugates in cancer